J. Grimm

发表

Comparison of non‐myeloablative and reduced‐intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes

G. Behre, D. Niederwieser, A. Hille, 2019, American journal of hematology.

Binding of Oxidized Low-Density Lipoprotein on Circulating Platelets Is increased in Patients With Acute Coronary Syndromes and Induces Platelet Adhesion to Vascular Wall In Vivo—Brief Report

T. Schönberger, D. Stakos, B. Bigalke, 2012, Arteriosclerosis, thrombosis, and vascular biology.

Mouse models of human non-small-cell lung cancer: raising the bar.

Keara M. Lane, A. Sweet-Cordero, T. Jacks, 2005, Cold Spring Harbor symposia on quantitative biology.

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation

D. Niederwieser, U. Platzbecker, S. Schwind, 2020, Bone Marrow Transplantation.

Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML

D. Niederwieser, U. Platzbecker, S. Schwind, 2020, Annals of Hematology.

Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients

G. Behre, D. Niederwieser, M. Cross, 2018, Annals of Hematology.

Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation

G. Behre, D. Niederwieser, M. Cross, 2018, Bone Marrow Transplantation.

Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning

G. Behre, D. Niederwieser, M. Cross, 2017, Bone Marrow Transplantation.

High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients

G. Behre, D. Niederwieser, S. Schwind, 2017, Oncotarget.

Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core

D. Heckl, J. Klusmann, J. Grimm, 2022, bioRxiv.

Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients

E. Willscher, H. Al-Ali, C. Dierks, 2022, Blood cancer journal.

Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation

D. Niederwieser, U. Platzbecker, S. Schwind, 2021, American journal of hematology.

Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation

D. Niederwieser, U. Platzbecker, S. Schwind, 2020, HemaSphere.

Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation

D. Niederwieser, U. Platzbecker, S. Schwind, 2021, Bone Marrow Transplantation.

Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation

D. Niederwieser, U. Platzbecker, S. Schwind, 2021, Blood Cancer Journal.

Treatment Options After a Diagnosis of Early Miscarriage: Expectant, Medical, and Surgical.

I. Juhasz-Böss, J. Grimm, Thabea Musik, 2021, Deutsches Arzteblatt international.

Molecular Mechanisms of the Genetic Predisposition to Acute Megakaryoblastic Leukemia in Infants With Down Syndrome

D. Heckl, J. Klusmann, J. Grimm, 2021, Frontiers in Oncology.

Metastatic risk stratification of clear cell renal cell carcinoma patients based on genomic aberrations

M. Stöckle, A. Hartmann, K. Junker, 2019, Genes, chromosomes & cancer.

Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation.

D. Niederwieser, U. Platzbecker, S. Schwind, 2020, Blood advances.

Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)

M. Scholz, U. Platzbecker, S. Schwind, 2021, Journal of Cancer Research and Clinical Oncology.

Pretreatment CD34+/CD38- Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation.

G. Behre, D. Niederwieser, S. Schwind, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia

G. Behre, D. Niederwieser, M. Cross, 2019, HemaSphere.

High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population.

G. Behre, D. Niederwieser, U. Platzbecker, 2020, Haematologica.

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation

D. Niederwieser, U. Platzbecker, S. Schwind, 2022, Blood advances.

Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation

D. Niederwieser, U. Platzbecker, S. Schwind, 2021, American journal of hematology.

Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation

G. Behre, D. Niederwieser, M. Cross, 2018, Bone Marrow Transplantation.

Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.

S. Schwind, D. Backhaus, M. Jentzsch, 2023, Leukemia.